Precigen Inc Stock Price, News & Analysis

Precigen (Nasdaq: PGEN) announced significant developments in its clinical programs and financial performance for Q1 2022. The FDA granted Fast Track designation for PRGN-3006 UltraCAR-T®, aimed at treating relapsed or refractory acute myeloid leukemia (AML). The company initiated a Phase 1b expansion for this therapy and began dosing at Dose Level 3 in the PRGN-3005 UltraCAR-T® trial for ovarian cancer. Financial results showed a 31% increase in total revenues to $32.0 million, with cash reserves at $142.1 million. Losses from operations decreased to $19.3 million.

Precigen, Inc. (Nasdaq: PGEN) has received FDA Fast Track designation for its PRGN-3006 UltraCAR-T therapy targeting relapsed or refractory acute myeloid leukemia (AML). This designation aims to expedite the development of this innovative treatment, which has shown a favorable safety profile with no dose-limiting toxicities. Previously, PRGN-3006 was granted orphan drug designation for AML patients. This advancement, supported by Precigen's proprietary non-viral gene delivery process, aligns with the urgent need for effective therapies in treating AML.

Precigen, Inc. (Nasdaq: PGEN) announced its fourth quarter and full year 2021 financial results, showcasing a notable 25% increase in total revenues year-over-year. The company reported a net loss of $25 million for Q4, improving from a loss of $39.7 million in the prior year. Key developments include the completion of various clinical trials and a public offering that raised approximately $129.4 million. The company anticipates current cash reserves will fund operations into 2023, supporting its clinical programs focused on gene and cell therapies.

On January 12, 2022, Precigen (PGEN) showcased key updates at the 40th Annual J.P. Morgan Healthcare Conference. Highlights included the completion of enrollment in several Phase 1/1b clinical trials for investigational therapies targeting Acute Myeloid Leukemia (AML), ovarian cancer, and recurrent respiratory papillomatosis (RRP). Notably, the firm reported positive interim data from multiple studies, with plans to initiate multicenter expansions and incorporate repeat dosing regimens. Additionally, Precigen aims for rapid regulatory strategies for its therapies addressing significant unmet medical needs in 2022.

Precigen, a biopharmaceutical company listed on Nasdaq under the ticker PGEN, announced that CEO Helen Sabzevari will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:45 PM ET. Additionally, she will join a panel discussion on January 11, 2022, at 12:00 PM ET, discussing the cell and gene therapy landscape. Live webcasts of both events can be accessed on Precigen's website.

Precigen presented promising interim results for its PRGN-3006 UltraCAR-T therapy targeting relapsed or refractory acute myeloid leukemia (AML) at the 63rd ASH Annual Meeting. The Phase 1/1b study included 15 patients, showing an overall response rate (ORR) of 50% in the lymphodepletion cohort. Notably, the therapy was well-tolerated, with no dose-limiting toxicities or neurotoxicity. The company anticipates progressing to a multicenter expansion phase to evaluate repeated dosing. These results highlight the potential of UltraCAR-T in transforming AML treatment pathways.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, will have its President and CEO, Helen Sabzevari, participate in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 10:40 AM ET. This event can be accessed via the Precigen website. The company is focused on gene and cell therapies aimed at treating urgent diseases, including in the areas of immuno-oncology and autoimmune disorders. More information can be found on their website.

Precigen (Nasdaq: PGEN) announced significant clinical progress during its 2021 R&D Day, showcasing advancements in its UltraCAR-T and AdenoVerse therapy platforms. Highlights include favorable safety and efficacy data from PRGN-3005, PRGN-3006, PRGN-2009, and PRGN-2012 therapies. Notably, PRGN-3006 demonstrated a 50% overall response rate in relapsed or refractory AML patients. Additionally, PRGN-2009 showed promising immune responses in HPV-associated cancers. Future plans include pursuing registrational trials pending dose confirmation. Overall, the event emphasized Precigen's commitment to advancing innovative therapies for complex diseases.

Precigen (Nasdaq: PGEN) will host a virtual event on November 4, 2021, at 11:00 AM ET to discuss updates on its clinical pipeline. The event will present data on several advanced programs, including PRGN-3005 and PRGN-3006 UltraCAR-T, as well as PRGN-2009 and PRGN-2012 AdenoVerse Immunotherapies. Executives and lead investigators from notable institutions will participate. Details for registration and access to the live webcast are available on Precigen's investor relations website.